Start-Up

This year, the Pre-GoBio program is supporting two planned spin-offs. Paul Schöpe aims to bring a drug targeting colorectal cancer metastases to market. And Ines Lahmann will further develop NMJCare, a model that can be used to test therapies for neuromuscular diseases.

Researchers at the Max Delbrück Center have developed a fast, cost-effective blood-based tool that can identify and classify immune deficiencies with high accuracy. The approach, published in “Nature Communications,” could help address long-standing gaps in diagnosing immune disorders.

Discovery, invention and spin-offs – Nevine Shalaby, Head of Innovation & Entrepreneurship was interviewed by “Buch Inside” about the path from research to innovation. She discusses how her team supports marketable research discoveries made at the Max Delbrück Center.

During the Predictive Systems Medicine Partnering Event at the Max Delbrück Center, researchers and industry representatives shared insights and explored commercialization opportunities – advancing our mission to turn discovery into real-world health impact.

A team led by Mina Gouti has developed a stem cell-based model that enables researchers to test new drugs to treat neuromuscular diseases and to refine existing therapies. The project, called NMJCare, was named one of the top ten ideas in the national Science4Life start-up competition.

Captain T Cell, a biotechnology spin-off from the Max Delbrück Center in Berlin, recently closed an equity financing round with both new and existing investors. It provides Captain T Cell with a total budget of EUR 20 million to develop next-generation T cell therapies for solid tumors.

What does it take to turn Max Delbrück Center research into a startup? Meet Klaas Yperman, our very first Entrepreneur-in-Residence. Yperman has won a Helmholtz Enterprise grant to develop a roadmap for turning compounds discovered in the Lewin lab into a drug to treat neuropathic pain.

The first VC Day at the Max Delbrück Center brought together our budding entrepreneurs with the CLIC incubator and top venture capital working in Berlin biotechnology for a day of pitching, exchange and networking.

Captain T Cell, a spin-off from the Max Delbrück Center, raised €8.5 million in startup funding. The startup focuses on developing T cells to target solid tumors. The funds are intended to move a new generation of T cell therapies towards the clinic.

Diseases can emerge when the body’s production of serotonin is out of whack. Researchers led by Michael Bader from the Max Delbrück Center have discovered a therapeutic agent that brings down high levels of this hormone. Their start-up, Trypto Therapeutics, aims to develop the drug for the market.